Cargando…
“Drugs to avoid” to improve quality use of medicines: how is Australia faring?
BACKGROUND: Each year, the French independent bulletin Prescrire publishes a list of medicines, “Drugs to avoid”, that should not be used in clinical practice as their risk-to-benefit ratio is unfavourable. This study assessed the market approval, reimbursement and use of these medicines in Australi...
Autores principales: | Vitry, Agnes, Mintzes, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278758/ https://www.ncbi.nlm.nih.gov/pubmed/34256874 http://dx.doi.org/10.1186/s40545-021-00346-3 |
Ejemplares similares
-
Access to new cancer medicines in Australia: dispelling the myths and informing a public debate
por: Vitry, Agnes, et al.
Publicado: (2016) -
Policing the promotion of prescription medicines – the new Medicines Australia Code of Conduct
por: Mintzes, Barbara
Publicado: (2021) -
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
por: Vitry, Agnes
Publicado: (2015) -
Assessment of the therapeutic value of new medicines marketed in Australia
por: Vitry, Agnes I, et al.
Publicado: (2013) -
Neutrino interactions: How does charm fare?
por: Gaillard, Mary Katherin
Publicado: (1976)